Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
10:41am, Thursday, 30'th Jan 2025
Here is how argenex SE (ARGX) and Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for January 20th
11:01am, Monday, 20'th Jan 2025
ARGX, ALLT and NGD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 20, 2025.
New Strong Buy Stocks for January 20th
07:51am, Monday, 20'th Jan 2025
TV, ALLT, CMTG, PLBC and ARGX have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2025.
Earnings Estimates Rising for Argenx (ARGX): Will It Gain?
01:21pm, Friday, 17'th Jan 2025
Argenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are Medical Stocks Lagging Argenx (ARGX) This Year?
10:40am, Tuesday, 14'th Jan 2025
Here is how argenex SE (ARGX) and Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) have performed compared to their sector so far this year.
argenx Highlights 2025 Strategic Priorities
01:00am, Monday, 13'th Jan 2025
Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
01:00am, Monday, 06'th Jan 2025
January 6, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today
VYVDURA ® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP
argenx to Present at Upcoming Investor Conferences
01:00am, Tuesday, 26'th Nov 2024
November 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, tod
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
01:00am, Wednesday, 20'th Nov 2024
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIA Potential for efgartigim
Argenx upgraded to Outperform from Peer Perform at Wolfe Research
04:41pm, Monday, 11'th Nov 2024
Wolfe Research upgraded Argenx to Outperform from Peer Perform.
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
07:30am, Monday, 11'th Nov 2024
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China's National Medical Products Administration (NMP
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
07:30am, Monday, 11'th Nov 2024
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx SE
Why Argenx (ARGX) Might be Well Poised for a Surge
01:21pm, Tuesday, 05'th Nov 2024
Argenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
10:45am, Tuesday, 05'th Nov 2024
Here is how argenex SE (ARGX) and Novartis (NVS) have performed compared to their sector so far this year.
